More Emyria Ltd news
Emyria LtdASX: EMD

Positive results received for Emyrias MDMA-inspired program

Aug 17, 2022 at 11:49 PM EDT · Issued by Emyria Ltd

Filed with ASX · Aug 17, 2022 at 11:49 PM EDT

On 6ix: 6ix.com/news/positive-results-received-for-emyrias-mdma-inspired-program

Emyria Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Emyria Ltd on 6ix

Earlier from Emyria

  • Emyria receives ethics approval for EMD-RX5 Phase 3 trialAug 16, 2022
  • Preclinical studies initiated for MDMA-inspired analoguesAug 4, 2022
  • Appendix 4C - QuarterlyJul 27, 2022
  • Emyria expands drug candidate library inspired by MDMAJul 17, 2022
  • Emyria expands MDMA analogue program with UWAMay 31, 2022

Later from Emyria

  • Appendix 4E and Annual ReportAug 29, 2022
  • Emyria commences US preclinical program for MDMA librarySep 19, 2022
  • Emyria expands clinical sites for EMD-RX5 Phase 3 trialSep 25, 2022
  • Emyria and UWA expand unique MDMA-inspired analogue libraryOct 17, 2022
  • Emyria completes $3m placementOct 30, 2022
All Emyria news releases↗

Follow Emyria into a list and get an email when it puts out news.

Follow Emyria
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer